Outcomes after prostate brachytherapy are even better than predicted

Cancer

Volumn 118, Issue 3, 2012, Pages 839-847

  Frank, Steven J ^a   Levy, Lawrence B ^a   Van Vulpen, Marco ^b   Crook, Juanita ^c,e   Sylvester, John ^d,f   Grimm, Peter ^d,g   Pugh, Thomas J ^a   Swanson, David A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d Seattle Prostate Institute   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Lakewood Ranch Oncology Center   (United States)

^g Prostate Cancer Treatment Center   (United States)

Author keywords

low dose rate brachytherapy; nomogram; prostate cancer; prostate specific antigen bounce; prostogram; quality of life; radiation oncology; radiation therapy; radioactive seeds

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES; UNIVERSITY HOSPITAL;

BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NOMOGRAMS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84856233701     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26307     Document Type: Article

References (24)

1. American Cancer Society. Cancer Facts and Figures, 2010. Accessed June 13, 2011.
2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Accessed June 13, 2011.
3. Memorial Sloan-Kettering Cancer Center. Prostate Cancer Nomograms: 2009. Accessed June 13, 2011.
4. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358: 1250-1261.
5. Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA,. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol. 2007; 177: 2151-2156.
6. Frank SJ, Levy LB, Kuban DA, et al. Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the MD Anderson Cancer Center experience with 125-iodine brachytherapy. J Urol. 2009; 181: 1658-1664.
7. Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK,. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998; 41: 101-108.
8. Harrell FE,. Regression Modeling Strategies. New York: Springer-Verlag; 2006.
9. Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology. 2001; 58: 393-399.
10. Caloglu M, Ciezki J,. Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon. Urology. 2009; 74: 1183-1190.
11. Wallner KE, Blasko J, Datolli M,. Prostate Brachytherapy Made Complicated. Seattle, WA: SmartMedicine; 1997.
12. Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA,. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol. 2000; 163: 1085-1089.
13. Cavanagh W, Blasko JC, Grimm PD, Sylvester JE,. Transient elevation of serum prostate-specific antigen following I/Pd brachytherapy for localized prostate cancer. Semin Urol Oncol. 2000; 18: 160-165.
14. Das P, Chen MH, Valentine K, et al. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int J Radiat Oncol Biol Phys. 2002; 54: 698-702.
15. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL,. Prostate-specific antigen spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2002; 54: 450-456.
16. Stock RG, Stone NN, Cesaretti JA,. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys. 2003; 56: 448-453.
17. Critz FA, Williams WH, Levinson AK, et al. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. J Urol. 2003; 170: 1864-1867.
18. Crook J, Gillan C, Yeung I, Austen L, McLean M, Lockwood G,. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2007; 69: 426-433.
19. 125 permanent seed implant for localised prostate cancer. Radiother Oncol. 2008; 88: 102-107.
20. 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis. BJU Int. 2009; 103: 1064-1068.
21. Kanai K, Nakashima J, Sugawara A, et al. Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer. Int J Clin Oncol. 2009; 14: 502-506.
22. Zwahlen DR, Smith R, Andrianopoulos N, Matheson B, Royce P, Millar JL,. Prostate-specific antigen bounce after permanent iodine-125 prostate brachytherapy-an Australian analysis. Int J Radiat Oncol Biol Phys. 2011; 79: 179-187.
23. Zelefsky MJ,. PSA bounce versus biochemical failure following prostate brachytherapy. Nat Clin Pract Urol. 2006; 3: 578-579.
24. Savage CJ, Vickers AJ,. Low annual caseloads of United States surgeons conducting radical prostatectomy. J Urol. 2009; 182: 2677-2681.